News Briefing channel feed

Glob­al Blood Ther­a­peu­tics buoyed by good news from FDA; Cigna to help cov­er pricey ther­a­pies

6 years ago

Bris­tol-My­ers is scout­ing new com­pa­ny star­tups; Ab­b­Vie and Idera team up to eval­u­ate com­bi­na­tion for HN­SCC

6 years ago

A PhII flop trig­gers an ug­ly rout for mi­cro-cap biotech Aridis; Gen­fit CEO pass­es ba­ton to suc­ces­sor

6 years ago

Paratek pub­lish­es pos­i­tive PhI­II da­ta on ap­proved Nuzyra; Al­ler­gan set­tles opi­oid law­suits in two Ohio coun­ties

6 years ago

Es­pe­ri­on re­leas­es pos­i­tive PhII re­sults; Safe­ty warn­ings at In­dia, Chi­na man­u­fac­tur­ing sites spell trou­ble for glob­al sup­ply chain

6 years ago

Alex­ion's cash cow re­ceives la­bel ex­pan­sion; Matthew Dal­las tapped to CFO post at Zealand Phar­ma

6 years ago

GSK work­ers may be in trou­ble with UK au­thor­i­ties; EU pledges €550M to fight AIDS, tu­ber­cu­lo­sis and malar­ia

6 years ago

ADC Ther­a­peu­tics signs pact with Freenome; Shang­hai Hen­lius Biotech eyes $600M for Hong Kong IPO

6 years ago

Pfiz­er, Astel­las win pri­or­i­ty re­view for Xtan­di sN­DA; Hemi­spherx changes its name

6 years ago

BeiGene and Mus­tang nail down spe­cial FDA sta­tus for top drugs; Roche bags added cov­er­age for Hem­li­bra

6 years ago

GSK sub­mits its first ap­pli­ca­tion for dapro­du­s­tat in Japan; Two drug­mak­ers part with $15M to avoid opi­oid tri­al

6 years ago

Pfiz­er Foun­da­tion of­fers $2M in grants to NGOs tack­ling an­timi­cro­bial re­sis­tance; Bio­gen, In­vi­tae join forces to de­vel­op faster SMA di­ag­nos­tic

6 years ago

Glen­mark launch­es Re­mogliflozin com­bo in In­dia; Gene­Cen­tric Ther­a­peu­tics buys Se­lect Im­munoGenomics

6 years ago

Soar­ing De­ci­phera cap­i­tal­izes on pos­i­tive tri­al with $400M of­fer­ing; Spring­Work hires ex-For­est Labs CFO

6 years ago

Sen­a­tors ac­cuse Te­va, My­lan of stonewalling price fix­ing probe; Myr­i­ad Ge­net­ics shares skid on dis­mal quar­ter­ly re­sults

6 years ago

Re­gen­eron's pre-filled Eylea sy­ringe makes the FDA cut; Cure­Vac inks pact with Yale

6 years ago

Ebo­la tri­al stopped ear­ly as Re­gen­eron, Ridge­back ther­a­pies cut death risk; Mer­ck inks deal to test Keytru­da with On­colo­gie's an­ti­body

6 years ago

FDA re­jects Kala's dry eye drug; Trou­bled In­sys finds a buy­er (of some as­sets) in Hik­ma

6 years ago

Boris John­son pledges £250M to spur AI adop­tion in NHS; SQZ scoops CFO Teri Lox­am from Mer­ck

6 years ago

Athenex's oral chemother­a­py for­mu­la­tion scores in piv­otal study; Gly­comine brings in $33M in Se­ries B haul

6 years ago

FDA en­dors­es No­vavax's piv­otal tri­al de­sign for flu vac­cine; Forty Sev­en bags fund­ing for myelodys­plas­tic syn­dromes pro­gram

6 years ago

Guardant blood test shows promise in pre­dict­ing im­munother­a­py re­sponse; As­traZeneca's di­a­betes drug wins EU la­bel ex­pan­sion

6 years ago

Am­i­cus touts lat­est set of gene ther­a­py da­ta; No­vo Nordisk ex­pands dis­cov­ery deal for di­a­betes

6 years ago

At­lantic Health­care's drug fails late-stage test; Trans­late Bio breaks out ear­ly CF da­ta

6 years ago
First page Previous page 47484950515253 Next page Last page
A service from the Financial Times